Trial
NCT05228821
Voxelotor Brain Oxygenation and Neurocognitive Study
Phase IVWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Pfizer
Collaborators
—
Condition
Sickle Cell Disease
Intervention
Voxelotor Oral Tablet
Why stopped
The study has been stopped due to Sponsor's business reasons. The termination is not a result of any safety concerns or change in the benefit-risk ratio.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-08-09